Two posters presented today at the American College of Rheumatology’s 2017 meeting in San Diego, California, highlight the gaps in US rheumatologists’ knowledge concerning biosimilar therapies, and underscore the importance of greater physician education about biosimilar medicines.
Two posters presented today at the American College of Rheumatology’s 2017 meeting in San Diego, California, highlight the gaps in US rheumatologists’ knowledge concerning biosimilar therapies, and underscore the importance of greater physician education about biosimilar medicines.
The first poster1 presented results of a survey, conducted by Allan Gibofsky, MD, and Sam Badawi, PharmD, that was developed to evaluate US rheumatologists’ familiarity with biosimilars. Areas of consideration included the concept of biosimilarity and the approval pathway for biosimilars.
The researchers administered a 20-question survey, using WebMD, between December 9-14, 2016. Respondents (n = 131) were members of Medscape.com, and had been invited via e-mail to participate in the survey. Data were collected from 102 participants who identified themselves as rheumatologists who had practiced in the United States for 1 year or longer. All but 1 respondent had prescribed an anti—tumor necrosis factor (anti-TNF) agent to treat a patient with an autoimmune disease.
When the physicians were asked to identify the status of biosimilars in the United States as of December 2016, 84% of respondents were aware that an infliximab had been approved by the FDA. However, only 47% were aware that the FDA had approved an adalimumab biosimilar, and only 34% were aware that the FDA had approved an etanercept biosimilar.
Most physicians had extreme (38%) or moderate (36%) familiarity with the FDA’s definition of a biosimilar, and most (71%) were aware that a biosimilar that gained FDA approval was not automatically deemed interchangeable.
Respondents also ranked the following as very important or moderately important:
With respect to initiating treatment, 66% were extremely likely or likely to initiate treatment with a biosimilar in treatment-naïve patients with rheumatoid arthritis if the approval of the biosimilar included efficacy and safety studies in the same indication, while fewer were extremely likely (5%) or likely (29%) to do so if the approval was based on data obtained from studies in another rheumatologic indication.
Approximately 60% of respondents were unlikely to switch from a reference biologic to a biosimilar in patients who were responding well to their current therapy. Additionally, 21% of respondents were extremely likely or likely to switch to a biosimilar if the patient was failing to respond well to the originator.
The researchers concluded that the results of this survey support a need to further educate US rheumatologists about biosimilars, the extrapolation of indications, and interchangeability, and that physicians have knowledge gaps that range from an understanding of the concept of biosimilarity to the availability of approved biosimilar therapies.
The second poster2 presented the findings of Janna Radtchenko, MBA, and colleagues, who conducted a survey of 24 community rheumatologists and 20 rheumatology practice managers during a live meeting in April 2017. The respondents represented practices of various sizes and geographic locations across the United States. The researchers, gathering data with the use of audience response technology, found the following:
Responses to the question “Which issues are most concerning?” included the following, in descending order of frequency:
Respondents named information about safety and efficacy, guidelines on when to prescribe a reference versus a biosimilar, and information about reimbursement as key tools for achieving a greater understanding of biosimilars.
The researchers concluded that physicians’ perceptions of biosimilars for rheumatologic indications present a significant barrier for the adoption of biosimilars, and that greater education may improve perceptions and facilitate more biosimilar usage.
References
1. Gibofsky A, Badawi S. Biosimilar knowledge among US rheumatologists—a survey. Presented at the American College of Rheumatology 2017 meeting, November 6, 2017; San Diego, California. Abstract 1037. acrabstracts.org/abstract/biosimilar-knowledge-among-us-rheumatologists-a-survey/.
2. Radtchenko J, Smith Y, Kish J, Feinberg B. Perceptions of US community rheumatologists on biosimilars. Presented at the American College of Rheumatology 2017 meeting, November 6, 2017; San Diego, California. Abstract 1040. acrabstracts.org/abstract/perceptions-of-us-community-rheumatologists-on-biosimilars/.
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).